{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T16:39:45Z","timestamp":1788194385097,"version":"build-2803163510"},"reference-count":109,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Liver Dis"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is increasing globally, creating a growing public health concern. However, this disease is often not diagnosed, and accurate data on its epidemiology are limited in many geographical regions, making it challenging to provide proper care and implement effective national plans. To combat the increasing disease burden, screening and diagnosis must reach a significant number of high-risk subjects. Addressing MASLD as a health care challenge requires a multidisciplinary approach involving prevention, diagnosis, treatment, and care, with collaboration between multiple stakeholders in the health care system. This approach must be guided by national and global strategies, to be combined with efficient models of care developed through a bottom-up process. This review article highlights the pillars of the MASLD model of care (MoC), including screening, risk stratification, and establishing a clinical care pathway for management, in addition to discussing the impact of nomenclature change on the proposed MoC.<\/jats:p>","DOI":"10.1055\/a-2253-9181","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T18:46:15Z","timestamp":1706208375000},"page":"054-068","source":"Crossref","is-referenced-by-count":10,"title":["Tailored Model of Care for Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease"],"prefix":"10.1055","volume":"44","author":[{"given":"Mohamed","family":"El-Kassas","sequence":"additional","affiliation":[{"name":"Endemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt"},{"name":"Steatotic Liver Disease Study Foundation in Middle East and North Africa (SLMENA), Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abeer","family":"Awad","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Elbadry","sequence":"additional","affiliation":[{"name":"Endemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt"},{"name":"Steatotic Liver Disease Study Foundation in Middle East and North Africa (SLMENA), Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Arab","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Schulich School of Medicine, Western University and London Health Sciences Centre, London, Ontario, Canada"},{"name":"Department of Epidemiology and Biostatistics, Schulich School of Medicine, Western University, London, Ontario, Canada"},{"name":"Department of Gastroenterology, School of Medicine, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,2,21]]},"reference":[{"issue":"03","key":"ref1","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1055\/a-1862-9088","article-title":"Nonalcoholic fatty liver disease: current global burden","volume":"42","author":"M El-Kassas","year":"2022","journal-title":"Semin Liver Dis"},{"issue":"06","key":"ref2","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"M E Rinella","year":"2023","journal-title":"J Hepatol"},{"issue":"06","key":"ref3","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"Letter to the editor: a multi-society Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"J H Hoofnagle","year":"2023","journal-title":"Hepatology"},{"issue":"01","key":"ref4","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"N Chalasani","year":"2018","journal-title":"Hepatology"},{"issue":"09","key":"ref5","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"K Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"01","key":"ref6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1614362","article-title":"Health effects of overweight and obesity in 195 countries over 25 years","volume":"377","author":"A Afshin","year":"2017","journal-title":"N Engl J Med"},{"issue":"04","key":"ref7","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S2213-8587(22)00003-1","article-title":"A global view of the interplay between non-alcoholic fatty liver disease and diabetes","volume":"10","author":"N Stefan","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2022.0365","article-title":"Global incidence and prevalence of nonalcoholic fatty liver disease","volume":"29","author":"M L Teng","year":"2023","journal-title":"Clin Mol Hepatol"},{"issue":"01","key":"ref9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Z M Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"02","key":"ref10","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.cld.2023.01.014","article-title":"Nonalcoholic fatty liver disease in Asia, Africa, and Middle East Region","volume":"27","author":"J Ong","year":"2023","journal-title":"Clin Liver Dis"},{"issue":"01","key":"ref11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s43856-022-00228-y","article-title":"A multistakeholder approach to innovations in NAFLD care","volume":"3","author":"J M Schattenberg","year":"2023","journal-title":"Commun Med (Lond)"},{"issue":"01","key":"ref12","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"M Eslam","year":"2020","journal-title":"J Hepatol"},{"issue":"10","key":"ref13","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/S2468-1253(21)00183-7","article-title":"Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement","volume":"6","author":"M Eslam","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"06","key":"ref14","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s12072-020-10094-2","article-title":"The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease","volume":"14","author":"M Eslam","year":"2020","journal-title":"Hepatol Int"},{"issue":"01","key":"ref15","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S2468-1253(20)30213-2","article-title":"Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa","volume":"6","author":"G Shiha","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"01","key":"ref16","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S2468-1253(20)30294-6","article-title":"Redefining fatty liver disease: an international patient perspective","volume":"6","author":"G Shiha","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"19","key":"ref17","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1097\/CM9.0000000000000981","article-title":"From NAFLD to MAFLD: a \u201credefining\u201d moment for fatty liver disease","volume":"133","author":"K I Zheng","year":"2020","journal-title":"Chin Med J (Engl)"},{"issue":"03","key":"ref18","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/hep.31420","article-title":"From NAFLD to MAFLD: implications of a premature change in terminology","volume":"73","author":"Z M Younossi","year":"2021","journal-title":"Hepatology"},{"issue":"06","key":"ref19","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.jhep.2020.08.028","article-title":"The times they are a-changin' (for NAFLD as well)","volume":"73","author":"V Ratziu","year":"2020","journal-title":"J Hepatol"},{"issue":"04","key":"ref20","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Z M Younossi","year":"2023","journal-title":"Hepatology"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12955-016-0420-z","article-title":"Non-alcoholic fatty liver disease (NAFLD) is associated with impairment of health related quality of life (HRQOL)","volume":"14","author":"P Golabi","year":"2016","journal-title":"Health Qual Life Outcomes"},{"issue":"12","key":"ref22","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s40273-015-0316-5","article-title":"Economic and quality-of-life implications of non-alcoholic fatty liver disease","volume":"33","author":"Z M Younossi","year":"2015","journal-title":"PharmacoEconomics"},{"issue":"11","key":"ref23","doi-asserted-by":"crossref","first-page":"e038190","DOI":"10.1136\/bmjopen-2020-038190","article-title":"Feedback of patient-reported outcomes to healthcare professionals for comparing health service performance: a scoping review","volume":"10","author":"S L Hancock","year":"2020","journal-title":"BMJ Open"},{"issue":"03","key":"ref24","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jval.2011.11.032","article-title":"A review of patient-reported outcome labels in the United States: 2006 to 2010","volume":"15","author":"A Gnanasakthy","year":"2012","journal-title":"Value Health"},{"issue":"01","key":"ref25","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2036.2008.03710.x","article-title":"Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"28","author":"Z M Younossi","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"issue":"03","key":"ref26","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s11136-006-9131-y","article-title":"Generic and disease-specific health related quality of life of liver patients with various aetiologies: a survey","volume":"16","author":"S M van der Plas","year":"2007","journal-title":"Qual Life Res"},{"issue":"07","key":"ref27","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1111\/j.1572-0241.2001.03956.x","article-title":"Health-related quality of life in chronic liver disease: the impact of type and severity of disease","volume":"96","author":"Z M Younossi","year":"2001","journal-title":"Am J Gastroenterol"},{"issue":"06","key":"ref28","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1002\/hep.30125","article-title":"Patient-reported outcomes and the economic effects of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: the value proposition","volume":"68","author":"Z M Younossi","year":"2018","journal-title":"Hepatology"},{"issue":"02","key":"ref29","doi-asserted-by":"crossref","first-page":"206","DOI":"10.5009\/gnl20127","article-title":"Recent epidemiology of nonalcoholic fatty liver disease","volume":"15","author":"S Murag","year":"2021","journal-title":"Gut Liver"},{"issue":"09","key":"ref30","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1111\/liv.14135","article-title":"Trends in hospitalizations for chronic liver disease-related liver failure in the United States, 2005-2014","volume":"39","author":"D Kim","year":"2019","journal-title":"Liver Int"},{"issue":"05","key":"ref31","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/lt.25443","article-title":"NASH is the most rapidly growing etiology for acute-on-chronic liver failure-related hospitalization and disease burden in the United States: a population-based study","volume":"25","author":"P Axley","year":"2019","journal-title":"Liver Transpl"},{"issue":"06","key":"ref32","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1002\/hep.30094","article-title":"Healthcare cost and utilization in nonalcoholic fatty liver disease: real-world data from a large U.S. claims database","volume":"68","author":"A M Allen","year":"2018","journal-title":"Hepatology"},{"issue":"02","key":"ref33","doi-asserted-by":"crossref","first-page":"181","DOI":"10.21037\/hbsn.2018.12.11","article-title":"Economic burden and healthcare utilization in nonalcoholic fatty liver disease","volume":"8","author":"E R Yoo","year":"2019","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"07","key":"ref34","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/j.cgh.2019.10.023","article-title":"Health care costs of patients with biopsy-confirmed nonalcoholic fatty liver disease are nearly twice those of matched controls","volume":"18","author":"H Hagstr\u00f6m","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"01","key":"ref35","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2005.04.014","article-title":"The natural history of nonalcoholic fatty liver disease: a population-based cohort study","volume":"129","author":"L A Adams","year":"2005","journal-title":"Gastroenterology"},{"issue":"02","key":"ref36","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11901-015-0258-6","article-title":"Long-term outcomes of nonalcoholic fatty liver disease","volume":"14","author":"M S Kwak","year":"2015","journal-title":"Curr Hepat Rep"},{"issue":"02","key":"ref37","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/hep.31040","article-title":"Attributable fractions of nonalcoholic fatty liver disease for mortality in the United States: results from the third national health and nutrition examination survey with 27 years of follow-up","volume":"72","author":"C S Alvarez","year":"2020","journal-title":"Hepatology"},{"issue":"04","key":"ref38","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/hep.26156","article-title":"Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States","volume":"57","author":"D Kim","year":"2013","journal-title":"Hepatology"},{"issue":"05","key":"ref39","first-page":"e25495","article-title":"Nonalcoholic fatty liver disease: an emerging modern-day risk factor for cardiovascular disease","volume":"14","author":"G Hassen","year":"2022","journal-title":"Cureus"},{"issue":"02","key":"ref40","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"P Angulo","year":"2015","journal-title":"Gastroenterology"},{"issue":"04","key":"ref41","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.jhep.2021.05.008","article-title":"Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease","volume":"75","author":"R Younes","year":"2021","journal-title":"J Hepatol"},{"issue":"06","key":"ref42","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1002\/hep.24268","article-title":"Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality","volume":"53","author":"Z M Younossi","year":"2011","journal-title":"Hepatology"},{"issue":"06","key":"ref43","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/hep.30664","article-title":"The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials","volume":"70","author":"A J Sanyal","year":"2019","journal-title":"Hepatology"},{"issue":"05","key":"ref44","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"65","author":"P S Dulai","year":"2017","journal-title":"Hepatology"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"100445","DOI":"10.1016\/j.eclinm.2020.100445","article-title":"Hospitalization costs and risk of mortality in adults with nonalcoholic steatohepatitis: analysis of a French national hospital database","volume":"25","author":"J Boursier","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"03","key":"ref46","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1381\/0960892053576820","article-title":"Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients","volume":"15","author":"J P Ong","year":"2005","journal-title":"Obes Surg"},{"issue":"04","key":"ref47","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1055\/s-0028-1091978","article-title":"The epidemiology of nonalcoholic fatty liver disease: a global perspective","volume":"28","author":"M Lazo","year":"2008","journal-title":"Semin Liver Dis"},{"issue":"14","key":"ref48","first-page":"1682","article-title":"Estimating global prevalence, incidence, and outcomes of non-alcoholic fatty liver disease from 2000 to 2021: systematic review and meta-analysis","volume":"135","author":"J Liu","year":"2022","journal-title":"Chin Med J (Engl)"},{"issue":"16","key":"ref49","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.3390\/diagnostics13162631","article-title":"Nonalcoholic fatty liver disease-related hepatocellular carcinoma: the next threat after viral hepatitis","volume":"13","author":"M Salaheldin","year":"2023","journal-title":"Diagnostics (Basel)"},{"issue":"01","key":"ref50","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/lt.25361","article-title":"Increasing incidence of nonalcoholic steatohepatitis as an indication for liver transplantation in Australia and New Zealand","volume":"25","author":"L Calzadilla-Bertot","year":"2019","journal-title":"Liver Transpl"},{"issue":"01","key":"ref51","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jhep.2019.08.027","article-title":"A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe","volume":"72","author":"J V Lazarus","year":"2020","journal-title":"J Hepatol"},{"issue":"06","key":"ref52","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S2468-1253(22)00008-5","article-title":"The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas","volume":"7","author":"L A D\u00edaz","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"01","key":"ref53","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/cld.1045","article-title":"Nonalcoholic fatty liver disease and recent guideline updates","volume":"17","author":"Y Ando","year":"2021","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"05","key":"ref54","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"M E Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.2337\/dc23-Srev","article-title":"Summary of Revisions: Standards of Care in Diabetes-2023","volume":"46","author":"N A ElSayed","year":"2023","journal-title":"Diabetes Care"},{"issue":"06","key":"ref57","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of nonalcoholic fatty liver disease","volume":"64","author":"European Association for the Study of the Liver (EASL)European Association for the Study of Diabetes (EASD)","year":"2016","journal-title":"J Hepatol"},{"issue":"01","key":"ref58","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/jgh.13857","article-title":"Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017\u2014Part 1: definition, risk factors and assessment","volume":"33","author":"V W Wong","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"issue":"06","key":"ref59","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jhep.2009.09.001","article-title":"Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study","volume":"51","author":"S Dasarathy","year":"2009","journal-title":"J Hepatol"},{"issue":"02","key":"ref60","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3390\/diagnostics12020407","article-title":"Diagnostic modalities of non-alcoholic fatty liver disease: from biochemical biomarkers to multi-omics non-invasive approaches","volume":"12","author":"E Martinou","year":"2022","journal-title":"Diagnostics (Basel)"},{"issue":"03","key":"ref61","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1136\/gutjnl-2019-318813","article-title":"Epidemiology of chronic liver diseases in the USA in the past three decades","volume":"69","author":"Z M Younossi","year":"2020","journal-title":"Gut"},{"issue":"03","key":"ref62","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","article-title":"Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults","volume":"34","author":"G Vernon","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"01","key":"ref63","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"C Estes","year":"2018","journal-title":"Hepatology"},{"issue":"06","key":"ref64","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jhep.2019.08.019","article-title":"Transient elastography for screening of liver fibrosis: cost-effectiveness analysis from six prospective cohorts in Europe and Asia","volume":"71","author":"M Serra-Burriel","year":"2019","journal-title":"J Hepatol"},{"issue":"01","key":"ref65","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12876-019-1039-4","article-title":"Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease","volume":"19","author":"A Srivastava","year":"2019","journal-title":"BMC Gastroenterol"},{"issue":"09","key":"ref66","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.mayocp.2022.04.005","article-title":"Nonalcoholic fatty liver disease: review of management for primary care providers","volume":"97","author":"R Basu","year":"2022","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"ref67","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.14309\/ajg.0000000000000388","article-title":"Histologic findings of advanced fibrosis and cirrhosis in patients with nonalcoholic fatty liver disease who have normal aminotransferase levels","volume":"114","author":"S Gawrieh","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"05","key":"ref68","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","article-title":"Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease","volume":"161","author":"F Kanwal","year":"2021","journal-title":"Gastroenterology"},{"issue":"10","key":"ref69","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41575-023-00798-9","article-title":"Measuring NAFLD models of care","volume":"20","author":"A M Allen","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"07","key":"ref70","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S2468-1253(21)00020-0","article-title":"Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach","volume":"6","author":"G Targher","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"05","key":"ref71","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","article-title":"American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD)","volume":"28","author":"K Cusi","year":"2022","journal-title":"Endocr Pract"},{"issue":"10","key":"ref72","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41575-021-00477-7","article-title":"Defining comprehensive models of care for NAFLD","volume":"18","author":"J V Lazarus","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"S 01","key":"ref73","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.5005\/jp-journals-10018-1359","article-title":"Holistic approach in the management of nonalcoholic fatty liver disease","volume":"12","author":"A Shrestha","year":"2022","journal-title":"Euroasian J Hepatogastroenterol"},{"issue":"05","key":"ref74","doi-asserted-by":"crossref","first-page":"100322","DOI":"10.1016\/j.jhepr.2021.100322","article-title":"Non-alcoholic fatty liver disease: a patient guideline","volume":"3","author":"S M Francque","year":"2021","journal-title":"JHEP Rep Innov Hepatol"},{"issue":"10","key":"ref75","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1016\/j.cgh.2021.01.023","article-title":"Weight loss and weight regain in usual clinical practice: results from the TARGET-NASH observational cohort","volume":"20","author":"M H Malespin","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"06","key":"ref76","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/joim.13203","article-title":"Discrepancies between actual weight, weight perception and weight loss intention amongst persons with NAFLD","volume":"289","author":"V H Nguyen","year":"2021","journal-title":"J Intern Med"},{"issue":"01","key":"ref77","doi-asserted-by":"crossref","first-page":"100411","DOI":"10.1016\/j.jhepr.2021.100411","article-title":"Real-world management of non-alcoholic steatohepatitis differs from clinical practice guideline recommendations and across regions","volume":"4","author":"Q M Anstee","year":"2021","journal-title":"JHEP Rep Innov Hepatol"},{"issue":"06","key":"ref78","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1002\/hep.32081","article-title":"Multidisciplinary clinic models: a paradigm of care for management of NAFLD","volume":"74","author":"S Kumar","year":"2021","journal-title":"Hepatology"},{"issue":"11","key":"ref79","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1111\/imj.16055","article-title":"Initial outcomes of a dedicated multidisciplinary non-alcoholic fatty liver disease clinic: a retrospective cohort study","volume":"53","author":"I Commins","year":"2023","journal-title":"Intern Med J"},{"issue":"02","key":"ref80","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jacc.2021.11.007","article-title":"Risk of heart failure in patients with nonalcoholic fatty liver disease: JACC review topic of the week","volume":"79","author":"A Mantovani","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"05","key":"ref81","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/liv.15209","article-title":"Knowledge of liver fibrosis stage among adults with NAFLD\/NASH improves adherence to lifestyle changes","volume":"42","author":"P Carrieri","year":"2022","journal-title":"Liver Int"},{"issue":"04","key":"ref82","first-page":"255","article-title":"Non-alcoholic fatty liver disease: a survey of involvement of primary care physicians","volume":"65","author":"A Mari","year":"2019","journal-title":"Minerva Gastroenterol Dietol"},{"issue":"06","key":"ref83","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","article-title":"Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association","volume":"42","author":"P B Duell","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"05","key":"ref84","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1365-2753.2005.00549.x","article-title":"Quality of care: the need for medical, contextual and policy evidence in primary care","volume":"11","author":"M L van Driel","year":"2005","journal-title":"J Eval Clin Pract"},{"issue":"04","key":"ref85","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1136\/jech.57.4.254","article-title":"Defining equity in health","volume":"57","author":"P Braveman","year":"2003","journal-title":"J Epidemiol Community Health"},{"issue":"S 02","key":"ref86","first-page":"S49","article-title":"Health equity: challenges in low income countries","volume":"9","author":"C G Orach","year":"2009","journal-title":"Afr Health Sci"},{"issue":"02","key":"ref87","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1257\/aer.89.2.306","article-title":"Urban-biased policies and rising income inequality in China","volume":"89","author":"D T Yang","year":"1999","journal-title":"Am Econ Rev"},{"issue":"08","key":"ref88","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1111\/j.1469-0691.2010.03280.x","article-title":"Economic evaluation of point-of-care diagnostic technologies for infectious diseases","volume":"16","author":"S Loubiere","year":"2010","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"ref89","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1056\/NEJMsa060247","article-title":"Cost-effectiveness of HIV treatment in resource-poor settings\u2014the case of C\u00f4te d'Ivoire","volume":"355","author":"S J Goldie","year":"2006","journal-title":"N Engl J Med"},{"issue":"05","key":"ref90","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1093\/ajcp\/aqy165","article-title":"The top 25 laboratory tests by volume and revenue in five different countries","volume":"151","author":"S Horton","year":"2019","journal-title":"Am J Clin Pathol"},{"issue":"10","key":"ref91","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.3390\/biomedicines11102809","article-title":"Gene variants implicated in steatotic liver disease: opportunities for diagnostics and therapeutics","volume":"11","author":"G Huang","year":"2023","journal-title":"Biomedicines"},{"issue":"11","key":"ref92","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.clnu.2023.09.022","article-title":"A nutrigenetic precision approach for the management of non-alcoholic fatty liver disease","volume":"42","author":"N Perez-Diaz-Del-Campo","year":"2023","journal-title":"Clin Nutr"},{"issue":"12","key":"ref93","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1080\/14728222.2021.2018418","article-title":"PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date","volume":"25","author":"A Cherubini","year":"2021","journal-title":"Expert Opin Ther Targets"},{"issue":"05","key":"ref94","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s11154-023-09820-6","article-title":"Towards precision medicine in non-alcoholic fatty liver disease","volume":"24","author":"S M Francque","year":"2023","journal-title":"Rev Endocr Metab Disord"},{"issue":"05","key":"ref95","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3390\/jpm13050830","article-title":"Precision medicine in fatty liver disease\/non-alcoholic fatty liver disease","volume":"13","author":"L Valenzuela-Vallejo","year":"2023","journal-title":"J Pers Med"},{"issue":"03","key":"ref96","first-page":"123","article-title":"Telemedicine in clinical practice: barriers and risks","volume":"162","author":"R Puchades","year":"2024","journal-title":"Med Cl\u00edn (Barc)"},{"issue":"02","key":"ref97","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s10620-021-06922-6","article-title":"Impact of a pilot structured mobile technology based lifestyle intervention for patients with nonalcoholic fatty liver disease","volume":"67","author":"M A Tincopa","year":"2022","journal-title":"Dig Dis Sci"},{"key":"ref98","doi-asserted-by":"crossref","first-page":"e37487","DOI":"10.2196\/37487","article-title":"The effectiveness of eHealth interventions on lifestyle modification in patients with nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"25","author":"O Y Kwon","year":"2023","journal-title":"J Med Internet Res"},{"issue":"06","key":"ref99","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/liv.15188","article-title":"The paradigm shift from NAFLD to MAFLD: a global primary care viewpoint","volume":"42","author":"T M Farahat","year":"2022","journal-title":"Liver Int"},{"issue":"01","key":"ref100","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41575-023-00846-4","article-title":"Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease","volume":"21","author":"G Feng","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"10","key":"ref101","doi-asserted-by":"crossref","first-page":"e0240984","DOI":"10.1371\/journal.pone.0240984","article-title":"How well are non-communicable disease services being integrated into primary health care in Africa: a review of progress against World Health Organization's African regional targets","volume":"15","author":"A G Tesema","year":"2020","journal-title":"PLoS One"},{"issue":"11","key":"ref102","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2471\/BLT.20.252742","article-title":"Measures to strengthen primary health-care systems in low- and middle-income countries","volume":"98","author":"E V Langlois","year":"2020","journal-title":"Bull World Health Organ"},{"issue":"09","key":"ref103","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1365-2036.2009.03961.x","article-title":"Screening for hepatitis B, C and non-alcoholic fatty liver disease: a survey of community-based physicians","volume":"29","author":"J B Kallman","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"35","key":"ref104","doi-asserted-by":"crossref","first-page":"5803","DOI":"10.3748\/wjg.v27.i35.5803","article-title":"Screening for nonalcoholic fatty liver disease-when, who and how?","volume":"27","author":"C G Dietrich","year":"2021","journal-title":"World J Gastroenterol"},{"issue":"02","key":"ref105","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s10620-022-07706-2","article-title":"Primary care providers and nonalcoholic fatty liver disease: a needs assessment survey","volume":"68","author":"K B Islam","year":"2023","journal-title":"Dig Dis Sci"},{"issue":"04","key":"ref106","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3390\/metabo13040536","article-title":"Screening for NAFLD\u2014current knowledge and challenges","volume":"13","author":"R Forlano","year":"2023","journal-title":"Metabolites"},{"issue":"04","key":"ref107","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/JXX.0000000000000223","article-title":"Readiness for the epidemic: the adult nonalcoholic fatty liver disease toolkit for primary care nurse practitioners","volume":"32","author":"K Casler","year":"2020","journal-title":"J Am Assoc Nurse Pract"},{"issue":"11","key":"ref108","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1111\/liv.15404","article-title":"Management of NAFLD in primary care settings","volume":"42","author":"V WS Wong","year":"2022","journal-title":"Liver Int"},{"issue":"06","key":"ref109","doi-asserted-by":"crossref","first-page":"e1456","DOI":"10.1016\/j.cgh.2021.06.048","article-title":"A global survey of physicians knowledge about nonalcoholic fatty liver disease","volume":"20","author":"Z M Younossi","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"07","key":"ref110","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/ueg2.12445","article-title":"A global survey of health care workers' awareness of non-alcoholic fatty liver disease: the AwareNASH survey","volume":"11","author":"S Driessen","year":"2023","journal-title":"United European Gastroenterol J"}],"container-title":["Seminars in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2253-9181.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T11:16:00Z","timestamp":1730805360000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2253-9181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,25]]},"references-count":109,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2024,4,16]]},"published-print":{"date-parts":[[2024,2]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2253-9181","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0272-8087","1098-8971"],"issn-type":[{"value":"0272-8087","type":"print"},{"value":"1098-8971","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1,25]]},"published":{"date-parts":[[2024,1,25]]}}}